跳转至内容
Merck

SML1975

Sigma-Aldrich

UCB35625

>97% (HPLC)

别名:

trans-1-(1-Cycloocten-1-ylmethyl)-4-[[(2,7-dichloro-9H-xanthen-9-yl)carbonyl]amino]-1-ethyl-piperidinium iodide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C30H37Cl2IN2O2
分子量:
655.44
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

>97% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C30H36Cl2N2O2.HI/c1-2-34(20-21-8-6-4-3-5-7-9-21)16-14-24(15-17-34)33-30(35)29-25-18-22(31)10-12-27(25)36-28-13-11-23(32)19-26(28)29;/h8,10-13,18-19,24,29H,2-7,9,14-17,20H2,1H3;1H/b21-8+;/t24-,34-;

InChI 密鑰

FOAFBMYSXIGAOX-MUMZCOSOSA-N

生化/生理作用

High affinity antagonist for CCR1 and CCR3 receptors, partial agonist at CCR2 and CCR5 receptors
UCB35625 is a high affinity antagonist for CCR1 and CCR3 receptors. Also both UCB35625 and its enantiomer J113863 exhibit low binding affinity toward CCR2 and CCR5 where they activate three Gi and two G0 protein isoforms. UCB35625 does not activate G12 protein isoform. J113863 binding to CCR2 and CCR5 induce the recruitment of b-arrestin 2 whereas UCB35625 did not. J113863 and UCB35625 are biased ligands for the chemokine receptors CCR2 and CCR5.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Filipa Lopes de Mendonça et al.
The Journal of biological chemistry, 280(6), 4808-4816 (2004-11-19)
The chemokine receptor CCR1 and its principal ligand, CCL3/MIP-1alpha, have been implicated in the pathology of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and asthma. As such, these molecules are the focus of much research with the ultimate aim
I Sabroe et al.
The Journal of biological chemistry, 275(34), 25985-25992 (2000-06-16)
We describe a small molecule chemokine receptor antagonist, UCB35625 (the trans-isomer J113863 published by Banyu Pharmaceutical Co., patent WO98/04554), which is a potent, selective inhibitor of CCR1 and CCR3. Nanomolar concentrations of UCB35625 were sufficient to inhibit eosinophil shape change

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门